Speaker: Date: Topic
Richard S. Beaser, MD
Mar. 8, 2017
Antidiabetes Medications: A Clinical Update
FDA Warning Links
Director of Medical Education and Committee Members have indicated they have no relevant financial interests or relationships to disclose. Faculty has indicated no relevant financial interests or relationships to disclose.
Take-Away Points of the Presentation
1. If lifestyle interventions and the initial one or two antidiabetes medications do not achieve recommended glycemic control goals for people with type 2 diabetes, advancement to further medical therapy should be made in a timely manner.
2. Glycemic control goals should be individualized and medication selection should be made with those individualized goals under consideration.
3. Understanding the pharmacology, usage parameters, and adverse event profiles of the newer antidiabetes medications can help you use these drugs more effectively.
4. Cardiovascular outcomes trials can provide additional insight into the usage of some antidiabetes medications in the context of how the trials were designed and the interpretation of the data.
Objectives of the Presentation
Participants should be able to:
- Describe how the pathophysiologic spectrum that is seen in people with type 2 diabetes can drive decisions on the design of antidiabetes medication treatment.
- Discuss the mechanisms of action, indications, adverse event potential of the newer classes of antidiabetes medications.
- Discuss how cardiovascular outcomes trials have provided another parameter to use in the design of individualized antidiabetes medication treatment programs.
Links to Abstracts of Articles Cited (contact Diane Young for full-text articles at firstname.lastname@example.org)
PDF of the PowerPoint Presentation
Major Antidiabetes Medications (Generic and Trade Names)
Responsibility for Content
The PowerPoint presentation, Take-Away points, Objectives, Links, and Abstract links were sent by Medical Library Services and the CME Committee.
Diane E. Young, Information Specialist